Phase 2 Chronic Graft Versus Host Disease Clinical Trials
17 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–17 of 17 trials
Recruiting
Phase 2
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
Lung DiseasesBronchiolitis Obliterans SyndromeChronic Graft Versus Host Disease+1 more
Dana-Farber Cancer Institute45 enrolled6 locationsNCT05922761
Recruiting
Phase 2
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
Chronic Graft Versus Host Disease
Sanofi37 enrolled33 locationsNCT07116031
Recruiting
Phase 2
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center82 enrolled5 locationsNCT05996627
Recruiting
Phase 2
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
Chronic Graft Versus Host Disease
Incyte Corporation60 enrolled41 locationsNCT07124078
Recruiting
Phase 2
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Chronic Graft Versus Host Disease
Syndax Pharmaceuticals296 enrolled121 locationsNCT04710576
Recruiting
Phase 2
A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT
Chronic Graft Versus Host DiseaseGraft vs Host Disease
WeiShi30 enrolled1 locationNCT07606703
Recruiting
Phase 2
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
Chronic Graft Versus Host DiseasecGVHD
University of Miami49 enrolled1 locationNCT06663722
Recruiting
Phase 2
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Chronic Graft Versus Host Disease
Northside Hospital, Inc.25 enrolled1 locationNCT06046248
Recruiting
Phase 2
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center50 enrolled3 locationsNCT07011810
Recruiting
Phase 2
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Chronic Graft Versus Host Disease
Incyte Corporation120 enrolled70 locationsNCT06388564
Recruiting
Phase 1Phase 2
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
Chronic Graft Versus Host Disease
Incyte Corporation30 enrolled9 locationsNCT06843408
Recruiting
Phase 2
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Hematopoietic and Lymphatic System NeoplasmChronic Graft Versus Host Disease
Mayo Clinic40 enrolled1 locationNCT06271616
Recruiting
Phase 1Phase 2
Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy
Chronic Graft Versus Host Disease
Yujun DONG24 enrolled1 locationNCT07012304
Recruiting
Phase 2
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.52 enrolled12 locationsNCT06300320
Recruiting
Phase 2
Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
Chronic Graft Versus Host Disease
Navy General Hospital, Beijing21 enrolled1 locationNCT02918188
Recruiting
Phase 2
A Phase II Study of the Impact of Two Different Schedules of Thymoglobulin on the Incidence of Extensive Chronic Graft Verus Host Disease (GVHD) in Patients Undergoing Unrelated Donor or Mismatched Related Donor Stem Cell Transplantation
Chronic Graft versus Host Disease in Haematology Malignancy Patients receiving donor stem cell transplantation
The Royal Melbourne Hospital120 enrolled1 locationACTRN12609000173291
Withdrawn
Phase 2
Prospective study of Rituximab for chronic graft vs host disease (GVHD) sub-optimally responsive to immunosuppressive therapy: Assessment of response.
Chronic graft versus host disease post allogeneic bone marrow transplant
Australasian Leukaemia and Lymphoma Group20 enrolled1 locationACTRN12606000326594